Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
This dual mechanism, eating less while burning more, accounts for the superior weight loss outcomes observed in clinical trials
Cross-indication switches (Wegovy to Mounjaro for diabetes, or Ozempic to Zepbound for obesity) require the appropriate qualifying diagnosis and often a new pre-authorization cycle
Alternatives for microdosing GLP-1 medications include a slower titration phase, switching to a different medication, or managing the side effects with lifestyle modifications
These shifts disrupt follicle development and ovulation
Data from liraglutide trials (a closely related GLP-1 agonist) demonstrated approximately a 7% increase in amylase and a 28% to 31% increase in lipase compared to placebo
Work closely with your healthcare team to find the approach that works best for you
US$ 22.16
US$ 27.64
US$ 20.68
US$ 20.29
US$ 22.26
US$ 29.21
